Department of Clinical Laboratory, Provincial Hospital Affiliated to Anhui Medical University, Hefei, 230022, China.
Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230022, China.
Eur J Pharmacol. 2022 Apr 15;921:174868. doi: 10.1016/j.ejphar.2022.174868. Epub 2022 Mar 3.
Quercetin, which is present in numerous fruits and vegetables, has shown promise in improving inflammation, lipid profiles, and blood pressure in humans. However, the efficacy of quercetin in diabetic nephropathy (DN) remains preclinical and unclear. Therefore, a meta-analysis based on preclinical animal data is needed to assess the efficacy, optimal dosage, and underlying mechanism of DN treatment to accelerate new drug research and clinical translation. We conducted a literature search in PubMed, Embase, Web of Science, and Cochrane Library to retrieve randomized controlled trials evaluating the effects of quercetin in rat or mouse diabetic models. We assessed the quality of the studies individually according to SYRCLE's risk of bias tool for animal studies. Twenty animal studies, including 378 animals, were included in the meta-analysis. Meta-analysis data showed that renal function indices, such as renal index, urine protein, uric acid, urine albumin, and serum creatinine levels, significantly improved with quercetin administration. However, no significant association was observed between quercetin and creatinine clearance. Quercetin remarkably alleviated oxidative stress by reducing malondialdehyde (MDA) and increasing superoxide dismutase (SOD) and catalase (CAT) activities. In addition, quercetin exhibits anti-inflammatory activity by reducing tumor necrosis factor-α（TNF-α）and interleukin-1β（IL-1β）levels. Subgroup analysis performed using quercetin doses and animal species indicated that animal species were a source of heterogeneity. This meta-analysis suggests that quercetin is a promising drug for DN treatment, facilitating clinical prediction and therapy.
槲皮素存在于许多水果和蔬菜中，已被证明可改善人体的炎症、血脂谱和血压。然而，槲皮素在糖尿病肾病（DN）中的疗效仍处于临床前阶段，尚不清楚。因此，需要基于临床前动物数据进行荟萃分析，以评估 DN 治疗的疗效、最佳剂量和潜在机制，从而加速新药研究和临床转化。我们在 PubMed、Embase、Web of Science 和 Cochrane Library 中进行了文献检索，以检索评估槲皮素在大鼠或小鼠糖尿病模型中作用的随机对照试验。我们根据 SYRCLE 动物研究偏倚风险工具单独评估了研究的质量。共有 20 项动物研究，包括 378 只动物，被纳入荟萃分析。荟萃分析数据表明，槲皮素治疗可显著改善肾功能指标，如肾指数、尿蛋白、尿酸、尿白蛋白和血清肌酐水平。然而，槲皮素与肌酐清除率之间没有显著相关性。槲皮素通过降低丙二醛（MDA）和增加超氧化物歧化酶（SOD）和过氧化氢酶（CAT）活性显著减轻氧化应激。此外，槲皮素通过降低肿瘤坏死因子-α（TNF-α）和白细胞介素-1β（IL-1β）水平发挥抗炎作用。使用槲皮素剂量和动物物种进行的亚组分析表明，动物物种是异质性的来源。这项荟萃分析表明，槲皮素是治疗糖尿病肾病的一种有前途的药物，有助于临床预测和治疗。
